​

PTC Therapeutics (PTCT) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

PTCT Stock Forecast

PTC Therapeutics stock forecast is as follows: an average price target of $48.00 (represents a 6.08% upside from PTCT’s last price of $45.25) and a rating consensus of 'Hold', based on 10 wall street analysts offering a 1-year stock forecast.

PTCT Price Target

The average price target for PTC Therapeutics (PTCT) is $48.00 based on 1-year price targets from 10 Wall Street analysts in the past 3 months, with a price target range of $52.00 to $45.00. This represents a potential 6.08% upside from PTCT's last price of $45.25.

PTCT Analyst Ratings

Hold

According to 10 Wall Street analysts, PTC Therapeutics's rating consensus is 'Hold'. The analyst rating breakdown for PTCT stock is 0 'Strong Buy' (0.00%), 3 'Buy' (30.00%), 5 'Hold' (50.00%), 2 'Sell' (20.00%), and 0 'Strong Sell' (0.00%).

PTC Therapeutics Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 27, 2024Joel BeattyRobert W. Baird$52.00$45.0915.34%14.92%
Oct 11, 2024Jeffrey HungMorgan Stanley$45.00$38.4816.94%-0.55%
Aug 26, 2024Colin BristowUBS$47.00$34.9934.32%3.87%
Jul 12, 2024Jeffrey HungMorgan Stanley$32.00$33.20-3.61%-29.28%
May 20, 2024Paul ChoiGoldman Sachs$32.00$40.12-20.24%-29.28%
May 20, 2024Kelly ShiJefferies$46.00$39.8115.55%1.66%
Apr 26, 2024Jeffrey HungMorgan Stanley$30.00$28.575.01%-33.70%
Dec 14, 2022Goldman Sachs$35.00$38.94-10.11%-22.65%
Jun 23, 2022Brian AbrahamsRBC Capital$46.00$38.2920.14%1.66%
Apr 05, 2022Kristen KluskaCantor Fitzgerald$63.00$43.6444.36%39.23%
Aug 31, 2021Colin BristowUBS$45.00$43.653.09%-0.55%

The latest PTC Therapeutics stock forecast, released on Nov 27, 2024 by Joel Beatty from Robert W. Baird, set a price target of $52.00, which represents a 15.34% increase from the stock price at the time of the forecast ($45.09), and a 14.92% increase from PTCT last price ($45.25).

PTC Therapeutics Price Target by Period

1M3M12M
# Anlaysts127
Avg Price Target$52.00$48.50$40.57
Last Closing Price$45.25$45.25$45.25
Upside/Downside14.92%7.18%-10.34%

In the current month, the average price target of PTC Therapeutics stock is $52.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 14.92% increase as opposed to PTC Therapeutics's last price of $45.25. This month's average price target is up 7.22% compared to last quarter, and up 28.17% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Oct 11, 2024Morgan StanleyEqual-WeightEqual-WeightHold
Sep 05, 2024Morgan StanleyEqual-WeightEqual-WeightHold
Sep 05, 2024Cowen & Co.HoldHoldHold
Aug 26, 2024UBSBuyUpgrade
Aug 09, 2024Cowen & Co.HoldHoldHold
Aug 09, 2024BarclaysEqual-WeightEqual-WeightHold
Jul 12, 2024Morgan StanleyEqual-WeightEqual-WeightHold
Jul 01, 2024Cantor FitzgeraldOverweightOverweightHold
Jun 20, 2024CitigroupSellSellHold
May 20, 2024CitigroupSellSellHold
May 20, 2024Goldman SachsSellSellHold
May 20, 2024JefferiesBuyBuyHold
May 20, 2024Raymond JamesUnderperformMarket PerformUpgrade
Sep 19, 2023Raymond JamesUnderperformUnderperformHold
Aug 04, 2023Raymond JamesOutperformOutperformHold
Jul 11, 2023Morgan StanleyEqual-WeightEqual-WeightHold
May 18, 2023Goldman SachsSellSellHold
Dec 14, 2022Goldman SachsSellInitialise
Oct 19, 2022Cantor FitzgeraldOverweightOverweightHold
Sep 12, 2022JefferiesBuyInitialise
Jun 23, 2022RBC CapitalSector PerformSector PerformHold
May 24, 2022Raymond JamesOutperformOutperformHold
Feb 23, 2022BarclaysEqual-WeightEqual-WeightHold

PTC Therapeutics's last stock rating was published by Morgan Stanley on Oct 11, 2024. The company gave PTCT a "Equal-Weight" rating, the same as its previous rate.

PTC Therapeutics Financial Forecast

PTC Therapeutics Revenue Forecast

Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20
Revenue----------------$307.06M$196.58M$213.81M$220.38M$167.41M$217.13M$165.53M$148.74M$165.23M$138.74M$116.68M$117.94M$118.86M$118.40M
Avg Forecast$593.37M$432.67M$415.21M$384.84M$338.77M$325.09M$291.25M$255.97M$226.77M$186.73M$170.33M$165.53M$213.45M$170.59M$183.28M$165.49M$314.96M$210.23M$206.99M$200.52M$188.38M$178.52M$162.12M$146.91M$150.83M$120.44M$110.13M$98.82M$113.35M$112.21M
High Forecast$1.18B$863.53M$828.68M$768.06M$676.12M$648.82M$581.27M$510.87M$452.59M$372.67M$339.95M$213.40M$344.51M$171.33M$183.28M$165.63M$320.66M$210.23M$413.11M$400.19M$375.98M$178.52M$162.12M$146.91M$150.83M$120.44M$110.13M$98.82M$113.35M$112.21M
Low Forecast$275.34M$200.77M$192.67M$178.58M$157.20M$150.85M$135.15M$118.78M$105.23M$86.65M$79.04M$112.02M$163.09M$169.84M$183.28M$165.35M$311.87M$210.23M$96.05M$93.05M$87.42M$178.52M$162.12M$146.91M$150.83M$120.44M$110.13M$98.82M$113.35M$112.21M
# Analysts222222221114945484544343545499
Surprise %----------------0.97%0.94%1.03%1.10%0.89%1.22%1.02%1.01%1.10%1.15%1.06%1.19%1.05%1.06%

PTC Therapeutics's average Quarter revenue forecast for Mar 24 based on 4 analysts is $165.49M, with a low forecast of $165.35M, and a high forecast of $165.63M. PTCT's average Quarter revenue forecast represents a -46.11% decrease compared to the company's last Quarter revenue of $307.06M (Dec 23).

PTC Therapeutics EBITDA Forecast

Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20
# Analysts222222221114945484544343545499
EBITDA----------------$-334.83M$-118.16M$-209.54M$-65.84M$-89.75M$-77.15M$-112.74M$-83.76M$-97.30M$-95.11M$-80.34M$-95.44M$-25.03M$-14.55M
Avg Forecast$-353.32M$-257.63M$-247.24M$-229.15M$-201.72M$-193.57M$-173.42M$-152.42M$-135.03M$-111.18M$-101.42M$-98.56M$-127.10M$-101.57M$-109.13M$-71.60M$-187.54M$-125.18M$-123.25M$-65.10M$-81.57M$-83.34M$-75.68M$-59.18M$-70.41M$-56.23M$-51.41M$-75.22M$-52.92M$-52.38M
High Forecast$-163.95M$-119.55M$-114.73M$-106.33M$-93.60M$-89.82M$-80.47M$-70.73M$-62.66M$-51.59M$-47.06M$-66.70M$-97.11M$-101.13M$-109.13M$-57.28M$-185.70M$-125.18M$-57.19M$-52.08M$-65.26M$-83.34M$-75.68M$-47.34M$-70.41M$-56.23M$-51.41M$-60.17M$-52.92M$-52.38M
Low Forecast$-705.15M$-514.18M$-493.43M$-457.34M$-402.59M$-386.33M$-346.11M$-304.19M$-269.49M$-221.90M$-202.42M$-127.07M$-205.14M$-102.02M$-109.13M$-85.93M$-190.93M$-125.18M$-245.98M$-78.11M$-97.89M$-83.34M$-75.68M$-71.01M$-70.41M$-56.23M$-51.41M$-90.26M$-52.92M$-52.38M
Surprise %----------------1.79%0.94%1.70%1.01%1.10%0.93%1.49%1.42%1.38%1.69%1.56%1.27%0.47%0.28%

undefined analysts predict PTCT's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than PTC Therapeutics's previous annual EBITDA (undefined) of $NaN.

PTC Therapeutics Net Income Forecast

Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20
# Analysts222222221114945484544343545499
Net Income----------------$-155.79M$-132.97M$-198.88M$-138.96M$-170.89M$-109.31M$-152.09M$-126.73M$-143.26M$-133.62M$-118.37M$-128.64M$-74.35M$-69.69M
Avg Forecast$217.45M$50.66M$52.64M$45.99M$12.95M$5.41M$-9.22M$-26.09M$-31.85M$-53.98M$-59.75M$-65.69M$-60.44M$-117.01M$-86.15M$-125.92M$-10.63M$-81.92M$-124.72M$-114.47M$-120.12M$-98.45M$-104.97M$-104.07M$-128.84M$-127.11M$-139.08M$-101.38M$-70.35M$-63.15M
High Forecast$498.96M$116.25M$120.78M$105.53M$29.71M$12.41M$-2.80M$-7.91M$-9.66M$-16.37M$-18.12M$22.95M$-35.52M$-35.48M$-26.12M$-100.74M$40.33M$-24.84M$-37.82M$-91.58M$-96.09M$-98.45M$-104.97M$-83.25M$-128.84M$-127.11M$-139.08M$-81.10M$-70.35M$-63.15M
Low Forecast$65.94M$15.36M$15.96M$13.95M$3.93M$1.64M$-21.16M$-59.85M$-73.07M$-123.85M$-137.09M$-125.85M$-75.66M$-268.48M$-197.67M$-151.10M$-32.26M$-187.98M$-286.18M$-137.37M$-144.14M$-98.45M$-104.97M$-124.88M$-128.84M$-127.11M$-139.08M$-121.66M$-70.35M$-63.15M
Surprise %----------------14.65%1.62%1.59%1.21%1.42%1.11%1.45%1.22%1.11%1.05%0.85%1.27%1.06%1.10%

PTC Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. PTCT's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

PTC Therapeutics SG&A Forecast

Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20
# Analysts222222221114945484544343545499
SG&A----------------$76.29M$80.89M$88.45M$86.91M$92.72M$80.12M$79.89M$73.27M$86.55M$69.25M$68.88M$61.09M$75.46M$57.84M
Avg Forecast$315.12M$229.78M$220.51M$204.38M$179.91M$172.65M$154.67M$135.94M$120.43M$99.17M$90.46M$87.91M$113.36M$90.59M$97.34M$72.81M$167.26M$111.65M$109.93M$66.19M$72.56M$94.80M$86.10M$60.17M$80.10M$63.96M$58.49M$48.15M$60.20M$59.59M
High Forecast$628.92M$458.59M$440.09M$407.90M$359.07M$344.57M$308.69M$271.31M$240.36M$197.91M$180.54M$113.33M$182.96M$90.99M$97.34M$87.37M$170.29M$111.65M$219.39M$79.42M$87.08M$94.80M$86.10M$72.20M$80.10M$63.96M$58.49M$57.78M$60.20M$59.59M
Low Forecast$146.23M$106.63M$102.32M$94.84M$83.48M$80.11M$71.77M$63.08M$55.88M$46.02M$41.98M$59.49M$86.61M$90.20M$97.34M$58.24M$165.62M$111.65M$51.01M$52.95M$58.05M$94.80M$86.10M$48.14M$80.10M$63.96M$58.49M$38.52M$60.20M$59.59M
Surprise %----------------0.46%0.72%0.80%1.31%1.28%0.85%0.93%1.22%1.08%1.08%1.18%1.27%1.25%0.97%

PTC Therapeutics's average Quarter SG&A projection for Mar 24 is $72.81M, based on 4 Wall Street analysts, with a range of $58.24M to $87.37M. The forecast indicates a -4.57% fall compared to PTCT last annual SG&A of $76.29M (Dec 23).

PTC Therapeutics EPS Forecast

Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20
# Analysts222222221114945484544343545499
EPS----------------$-0.00$-1.76$-0.00$-1.88$-2.35$-1.53$-2.13$-1.78$-2.03$-1.89$-1.68$-1.83$-1.10$-1.03
Avg Forecast$2.83$0.66$0.68$0.60$0.17$0.07$-0.12$-0.34$-0.41$-0.70$-0.78$-0.85$-0.79$-1.52$-1.12$-1.27$-0.14$-1.06$-1.62$-1.53$-1.59$-1.28$-1.37$-1.51$-1.68$-1.66$-1.81$-1.54$-0.92$-0.82
High Forecast$6.49$1.51$1.57$1.37$0.39$0.16$-0.04$-0.10$-0.13$-0.21$-0.24$0.30$-0.46$-0.46$-0.34$-0.39$0.52$-0.32$-0.49$-0.47$-0.48$-1.28$-1.37$-1.51$-1.68$-1.66$-1.81$-1.54$-0.92$-0.82
Low Forecast$0.86$0.20$0.21$0.18$0.05$0.02$-0.28$-0.78$-0.95$-1.61$-1.78$-1.64$-0.98$-3.49$-2.57$-2.92$-0.42$-2.44$-3.72$-3.52$-3.64$-1.28$-1.37$-1.51$-1.68$-1.66$-1.81$-1.54$-0.92$-0.82
Surprise %----------------0.02%1.65%0.00%1.23%1.48%1.19%1.56%1.18%1.21%1.14%0.93%1.18%1.20%1.25%

According to undefined Wall Street analysts, PTC Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to PTCT previous annual EPS of $NaN (undefined).

PTC Therapeutics Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
HEPAHepion Pharmaceuticals$0.52$70.0013361.54%Buy
VKTXViking Therapeutics$46.70$97.80109.42%Buy
IOVAIovance Biotherapeutics$7.81$12.4058.77%Buy
SRPTSarepta Therapeutics$125.76$187.2048.85%Buy
BPMCBlueprint Medicines$96.48$122.6027.07%Buy
KRYSKrystal Biotech$169.04$210.3324.43%Buy
MDGLMadrigal Pharmaceuticals$306.08$315.753.16%Buy
PTCTPTC Therapeutics$47.02$48.002.08%Hold

PTCT Forecast FAQ

Is PTC Therapeutics a good buy?

No, according to 10 Wall Street analysts, PTC Therapeutics (PTCT) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 30.00% of PTCT's total ratings.

What is PTCT's price target?

PTC Therapeutics (PTCT) average price target is $48 with a range of $45 to $52, implying a 6.08% from its last price of $45.25. The data is based on 10 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will PTC Therapeutics stock go up soon?

According to Wall Street analysts' prediction for PTCT stock, the company can go up by 6.08% (from the last price of $45.25 to the average price target of $48), up by 14.92% based on the highest stock price target, and down by -0.55% based on the lowest stock price target.

Can PTC Therapeutics stock reach $70?

PTCT's average twelve months analyst stock price target of $48 does not support the claim that PTC Therapeutics can reach $70 in the near future.

What is PTC Therapeutics's current price target trend?

1 Wall Street analyst forecast a $52 price target for PTC Therapeutics (PTCT) this month, up 14.92% from its last price of $45.25. Compared to the last 3 and 12 months, the average price target increased by 7.18% and decreased by -10.34%, respectively.

What are PTC Therapeutics's analysts' financial forecasts?

PTC Therapeutics's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $1.21B (high $2.42B, low $561.98M), average EBITDA is $-721M (high $-335M, low $-1.439B), average net income is $-16.954M (high $31.41M, low $-75.452M), average SG&A $643.17M (high $1.28B, low $298.45M), and average EPS is $-0.22 (high $0.408, low $-0.981). PTCT's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $1.83B (high $3.64B, low $847.37M), average EBITDA is $-1.087B (high $-505M, low $-2.17B), average net income is $366.75M (high $841.52M, low $111.22M), average SG&A $969.78M (high $1.94B, low $450.01M), and average EPS is $4.77 (high $10.94, low $1.45).

Did the PTCT's actual financial results beat the analysts' financial forecasts?

Based on PTC Therapeutics's last annual report (Dec 2023), the company's revenue was $937.82M, beating the average analysts forecast of $932.7M by 0.55%. Apple's EBITDA was $-440M, missing the average prediction of $-501M by -12.29%. The company's net income was $-627M, beating the average estimation of $-332M by 88.88%. Apple's SG&A was $332.54M, missing the average forecast of $455.03M by -26.92%. Lastly, the company's EPS was $-0.0084, missing the average prediction of $-4.359 by -99.81%. In terms of the last quarterly report (Dec 2023), PTC Therapeutics's revenue was $307.06M, missing the average analysts' forecast of $314.96M by -2.51%. The company's EBITDA was $-335M, beating the average prediction of $-188M by 78.54%. PTC Therapeutics's net income was $-156M, beating the average estimation of $-10.632M by 1365.33%. The company's SG&A was $76.29M, missing the average forecast of $167.26M by -54.39%. Lastly, the company's EPS was $-0.0021, missing the average prediction of $-0.138 by -98.48%